CVS Pharmacy Suspends Sale of Zantac Products—and More—Due to FDA Investigation
Monday, September 30, 2019
CVS Pharmacy has suspended the sale of all Zantac brand and CVS Health ranitidine products until further notice.
“This action is being taken out of an abundance of caution due to a recent Product Alert from the U.S. Food and Drug Administration (FDA) that ranitidine products may contain a low level of nitrosodimethylamine (NDMA), which is a probable human carcinogen,” writes CVS in their press release.
CVS adds that the products have not been recalled, and the FDA is not recommending that patients stop taking ranitidine.
GET THE LATEST BREAKING NEWS HERE -- SIGN UP FOR GOLOCAL FREE DAILY EBLASTHowever, customers who purchased the products can return them to CVS for a refund.
CVS will continue to sell other over-the-counter H2 Blockers, including Pepcid, Tagamet and its respective generic equivalents, famotidine and cimetidine.
FDA Investigation
Ranitidine is an H2 Blocker that is taken to provide heartburn relief.
The suspension of the products comes as the FDA is continuing to evaluate whether low levels of NDMA in ranitidine pose a risk to patients.
According to CVS, the levels that FDA is finding in ranitidine from preliminary tests barely exceed amounts found in common foods.
Related Articles
- HealthSource RI Teams With CVS Health to Make Paying Bills Easier
- Rory McIlroy Highlights 2018 CVS Health Charity Classic Field
- Bradley, Andrade & Henderson Win CVS Health Charity Classic
- CVS Forced to Apologize After Store Managers Call Police on Black Women Over a Coupon
- CVS Ranks Below Average for Customer Satisfaction, Reports J.D. Power
- CVS Health Expands Safe Drug Disposal at RI CVS Pharmacy Locations
- Kaplan Discusses Amazon, CVS and Uber on Business Monday on LIVE
- CVS Says No To Photoshopped Beauty Marketing Images
- CVS PAC Is One of the Largest Donors to Trump’s Campaign
- CVS’ Acquisition of Aetna Takes a Turn: CA Investigating Aetna
- CVS, Aetna Merger Approved by Department of Justice
- Whitcomb: Too High End in Providence? CVS and Health-Care Transformation; Pawtucket’s Future
- Prov Police Seek Help in Identifying Suspect Connected to CVS Robbery
- NEW: CVS Pharmacy to Pay $535K for Filling Invalid Prescriptions
- New Information Unveils CVS’ Role in Opioid Crisis
- CVS Stock Skyrockets
- CVS Faces National Boycott Over Birth Control Reimbursement Rate Feud
- Complex Times for CVS — Stock Performance and Federal Court Review of Aetna Deal
